Relebactam

Relebactam (imipenem and cilastatin) is an antibacterial combination drug used to treat a variety of bacterial infections. It is composed of imipenem, a beta-lactam antibiotic, and cilastatin, an enzyme inhibitor. Relebactam is used to treat serious infections caused by susceptible bacteria, including infections of the abdomen, skin and skin structure, female pelvic organs, and the respiratory tract. Relebactam is also used to treat complicated urinary tract infections.

Relebactam (previously known as MK-7655) is an investigational medication, meaning it has not yet been commercially available or approved for any medical use. While research is ongoing, here's what we know about Relebactam so far:

• Potential Use: Relebactam was being studied as a beta-lactamase inhibitor to combat antibiotic resistance in bacterial infections [1].
  • Beta-lactamase enzymes are produced by some bacteria and can break down certain antibiotics (beta-lactam antibiotics), rendering them ineffective [2].
  • Relebactam was designed to inhibit these enzymes, potentially allowing beta-lactam antibiotics to work effectively against resistant bacteria [1].
• How it Might Work: Relebactam binds to beta-lactamase enzymes, preventing them from breaking down beta-lactam antibiotics. This allows the antibiotics to reach and target the bacteria more effectively [1].
• Development Status: Clinical trials were investigating Relebactam in combination with other antibiotics for various bacterial infections [1]. However, recent information suggests that the development of Relebactam may be discontinued or significantly reduced [3].
• Important Considerations:
  • Due to its investigational status, Relebactam is not available for prescription or to treat any bacterial infection.
  • More research would have been needed to determine its effectiveness and safety profile compared to existing antibiotic resistance solutions.
  • If you have a bacterial infection, consult with a doctor regarding established antibiotic options. Self-treating with investigational drugs is not recommended and can be dangerous.